China Pharma Holdings, Inc. (CPHI)
USD 1.7
(13.04%)
USD 1.7
(13.04%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.01 Million USD | -13.48% |
| 2022 | 8.1 Million USD | -15.95% |
| 2021 | 9.64 Million USD | -11.27% |
| 2020 | 10.86 Million USD | -0.53% |
| 2019 | 10.92 Million USD | -11.41% |
| 2018 | 12.33 Million USD | -6.67% |
| 2017 | 13.21 Million USD | -15.15% |
| 2016 | 15.57 Million USD | -23.49% |
| 2015 | 20.35 Million USD | -8.05% |
| 2014 | 22.13 Million USD | -32.53% |
| 2013 | 32.8 Million USD | -39.81% |
| 2012 | 54.5 Million USD | -32.85% |
| 2011 | 81.16 Million USD | 9.11% |
| 2010 | 74.38 Million USD | 20.57% |
| 2009 | 61.69 Million USD | 21.05% |
| 2008 | 50.96 Million USD | 53.58% |
| 2007 | 33.18 Million USD | 51.93% |
| 2006 | 21.84 Million USD | 152.3% |
| 2005 | 8.65 Million USD | 37097.91% |
| 2004 | 23.27 Thousand USD | -78.86% |
| 2003 | 110.07 Thousand USD | 193.62% |
| 2002 | 37.49 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.36 Million USD | -36.28% |
| 2024 Q2 | 924.94 Thousand USD | -32.48% |
| 2023 Q2 | 1.09 Million USD | -43.99% |
| 2023 FY | 7.01 Million USD | -13.48% |
| 2023 Q1 | 1.96 Million USD | -32.89% |
| 2023 Q3 | 1.8 Million USD | 64.27% |
| 2023 Q4 | 2.14 Million USD | 19.2% |
| 2022 Q2 | 1.61 Million USD | 0.57% |
| 2022 Q3 | 1.96 Million USD | 21.87% |
| 2022 FY | 8.1 Million USD | -15.95% |
| 2022 Q1 | 1.6 Million USD | -44.49% |
| 2022 Q4 | 2.92 Million USD | 48.58% |
| 2021 FY | 9.64 Million USD | -11.27% |
| 2021 Q1 | 2.35 Million USD | -19.54% |
| 2021 Q2 | 2.41 Million USD | 2.42% |
| 2021 Q3 | 1.97 Million USD | -18.09% |
| 2021 Q4 | 2.88 Million USD | 46.03% |
| 2020 Q1 | 1.76 Million USD | -42.14% |
| 2020 FY | 10.86 Million USD | -0.53% |
| 2020 Q3 | 2.4 Million USD | -36.33% |
| 2020 Q2 | 3.77 Million USD | 113.77% |
| 2020 Q4 | 2.93 Million USD | 22.1% |
| 2019 Q1 | 2.92 Million USD | -9.67% |
| 2019 FY | 10.92 Million USD | -11.41% |
| 2019 Q3 | 2.37 Million USD | -7.49% |
| 2019 Q2 | 2.56 Million USD | -12.29% |
| 2019 Q4 | 3.04 Million USD | 28.25% |
| 2018 FY | 12.33 Million USD | -6.67% |
| 2018 Q4 | 3.24 Million USD | 41.09% |
| 2018 Q3 | 2.29 Million USD | -27.58% |
| 2018 Q2 | 3.17 Million USD | -12.22% |
| 2018 Q1 | 3.61 Million USD | -6.03% |
| 2017 Q2 | 2.91 Million USD | -11.2% |
| 2017 Q3 | 3.16 Million USD | 8.4% |
| 2017 Q4 | 3.84 Million USD | 21.68% |
| 2017 FY | 13.21 Million USD | -15.15% |
| 2017 Q1 | 3.28 Million USD | -37.57% |
| 2016 Q4 | 5.26 Million USD | 68.36% |
| 2016 FY | 15.57 Million USD | -23.49% |
| 2016 Q1 | 3.64 Million USD | -19.16% |
| 2016 Q2 | 3.54 Million USD | -2.7% |
| 2016 Q3 | 3.12 Million USD | -11.76% |
| 2015 Q4 | 4.5 Million USD | 0.54% |
| 2015 Q2 | 5.67 Million USD | -0.36% |
| 2015 Q1 | 5.69 Million USD | 70.95% |
| 2015 FY | 20.35 Million USD | -8.05% |
| 2015 Q3 | 4.47 Million USD | -21.06% |
| 2014 Q1 | 7.1 Million USD | -15.55% |
| 2014 Q2 | 6.13 Million USD | -13.72% |
| 2014 Q3 | 5.56 Million USD | -9.2% |
| 2014 Q4 | 3.33 Million USD | -40.16% |
| 2014 FY | 22.13 Million USD | -32.53% |
| 2013 Q1 | 8.24 Million USD | -29.16% |
| 2013 Q2 | 8.02 Million USD | -2.7% |
| 2013 Q3 | 8.11 Million USD | 1.12% |
| 2013 Q4 | 8.41 Million USD | 3.67% |
| 2013 FY | 32.8 Million USD | -39.81% |
| 2012 Q4 | 11.64 Million USD | -4.36% |
| 2012 FY | 54.5 Million USD | -32.85% |
| 2012 Q3 | 12.17 Million USD | -16.59% |
| 2012 Q2 | 14.59 Million USD | -9.25% |
| 2012 Q1 | 16.08 Million USD | -28.37% |
| 2011 FY | 81.16 Million USD | 9.11% |
| 2011 Q4 | 22.45 Million USD | 7.01% |
| 2011 Q3 | 20.98 Million USD | 7.08% |
| 2011 Q2 | 19.6 Million USD | 8.18% |
| 2011 Q1 | 18.11 Million USD | -24.42% |
| 2010 Q4 | 23.97 Million USD | 28.34% |
| 2010 Q3 | 18.68 Million USD | 12.32% |
| 2010 FY | 74.38 Million USD | 20.57% |
| 2010 Q2 | 16.63 Million USD | 10.12% |
| 2010 Q1 | 15.1 Million USD | -22.87% |
| 2009 Q2 | 13.6 Million USD | 4.69% |
| 2009 FY | 61.69 Million USD | 21.05% |
| 2009 Q4 | 19.58 Million USD | 26.14% |
| 2009 Q3 | 15.52 Million USD | 14.13% |
| 2009 Q1 | 12.99 Million USD | -15.43% |
| 2008 Q2 | 11.27 Million USD | -3.74% |
| 2008 Q4 | 15.36 Million USD | 21.82% |
| 2008 FY | 50.96 Million USD | 53.58% |
| 2008 Q3 | 12.61 Million USD | 11.81% |
| 2008 Q1 | 11.71 Million USD | 28.92% |
| 2007 FY | 33.18 Million USD | 51.93% |
| 2007 Q4 | 9.08 Million USD | 9.59% |
| 2007 Q1 | 7.23 Million USD | -10.93% |
| 2007 Q2 | 8.57 Million USD | 18.48% |
| 2007 Q3 | 8.29 Million USD | -3.23% |
| 2006 Q2 | 3.97 Million USD | -16.0% |
| 2006 Q1 | 4.73 Million USD | 0.0% |
| 2006 Q3 | 5.01 Million USD | 26.15% |
| 2006 Q4 | 8.12 Million USD | 61.94% |
| 2006 FY | 21.84 Million USD | 152.3% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | 8.65 Million USD | 37097.91% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | 2.59 Million USD | 0.0% |
| 2004 Q3 | - USD | 100.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | 23.27 Thousand USD | -78.86% |
| 2004 Q2 | -2500.00 USD | -113.54% |
| 2004 Q1 | 18.45 Thousand USD | 638.32% |
| 2003 Q4 | 2500.00 USD | -48.1% |
| 2003 Q2 | 14.72 Thousand USD | 189.92% |
| 2003 Q1 | 5079.00 USD | 31.92% |
| 2003 Q3 | 4817.00 USD | -67.29% |
| 2003 FY | 110.07 Thousand USD | 193.62% |
| 2002 FY | 37.49 Thousand USD | 0.0% |
| 2002 Q4 | 3850.00 USD | -95.55% |
| 2002 Q3 | 86.42 Thousand USD | 6208.39% |
| 2002 Q2 | 1370.00 USD | -84.11% |
| 2002 Q1 | 8624.00 USD | -64.96% |
| 2001 Q4 | 24.61 Thousand USD | 754.06% |
| 2001 Q3 | 2882.00 USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| cbdMD, Inc. | 24.15 Million USD | 70.974% |
| cbdMD, Inc. | 24.15 Million USD | 70.974% |
| Zomedica Corp. | 25.18 Million USD | 72.162% |